Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited.
复制标题
DOI：
10.1158/2159-8290.cd-20-1817
复制
发表时间：
2021-03
期刊：
影响因子：
28.2
通讯作者：
AACR COVID-19 and Cancer Task Force
中科院分区：
文献类型：
--
作者：
Ribas A;Sengupta R;Locke T;Zaidi SK;Campbell KM;Carethers JM;Jaffee EM;Wherry EJ;Soria JC;D'Souza G;AACR COVID-19 and Cancer Task Force
关于COVID-19的系列出版物支持癌症患者是特别脆弱的人群的观点。癌症和COVID-19之间存在多种风险因素，癌症护理和治疗会增加对病毒的暴露，并可能抑制自然免疫反应。现有证据支持以下结论，即癌症患者，特别是血液系统恶性肿瘤患者，应被视为优先接种COVID-19疫苗的极高风险人群。
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.